The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Tóm tắt
Từ khóa
Tài liệu tham khảo
Grande, 2011, Targeting oncogenic ALK: a promising strategy for cancer treatment, Mol Cancer Ther, 10, 569, 10.1158/1535-7163.MCT-10-0615
Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886
Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440
Katayama, 2015, Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine, Clin Cancer Res, 21, 2227, 10.1158/1078-0432.CCR-14-2791
Toyokawa, 2015, Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data, Oncol Res Treat, 38, 291, 10.1159/000430852
Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948
Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539
Friboulet, 2014, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer, Cancer Discov, 4, 662, 10.1158/2159-8290.CD-13-0846
Sakamoto, 2011, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant, Cancer Cell, 19, 679, 10.1016/j.ccr.2011.04.004
Gadgeel, 2014, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol, 15, 1119, 10.1016/S1470-2045(14)70362-6
Shaw, 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 370, 1189, 10.1056/NEJMoa1311107
Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443
Ou, 2015, I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib, Lung Cancer, 88, 231, 10.1016/j.lungcan.2015.02.005
Ou, 2014, Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib, J Thorac Oncol, 9, 1821, 10.1097/JTO.0000000000000368
Ou, 2016, ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression, Lung Cancer, 91, 70, 10.1016/j.lungcan.2015.09.006
Iwama, 2014, Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer, Onco Targets Ther, 7, 375
Hatcher, 2015, Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation, J Med Chem, 58, 9296, 10.1021/acs.jmedchem.5b01136
Katayama, 2015, Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer, Clin Cancer Res, 21, 166, 10.1158/1078-0432.CCR-14-1385
Shaw, 2016, Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F, N Engl J Med, 374, 54, 10.1056/NEJMoa1508887
Katayama, 2014, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib, Clin Cancer Res, 20, 5686, 10.1158/1078-0432.CCR-14-1511
Talpaz, 2006, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias, N Engl J Med, 354, 2531, 10.1056/NEJMoa055229
Kantarjian, 2006, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL, N Engl J Med, 354, 2542, 10.1056/NEJMoa055104
Cortes, 2013, A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias, N Engl J Med, 369, 1783, 10.1056/NEJMoa1306494
Deininger, 2016, Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients, Blood, 127, 703, 10.1182/blood-2015-08-660977
Smith, 2013, A proposal regarding reporting of in vitro testing results, Clin Cancer Res, 19, 2828, 10.1158/1078-0432.CCR-13-0043
Iwahara, 1997, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system, Oncogene, 14, 439, 10.1038/sj.onc.1200849
Zhang, 2015, The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first-and second-generation ALK TKIs in preclinical models, Cancer Res, 75, 781, 10.1158/1538-7445.AM2015-781
Fontana, 2015, Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK, Cancer Med, 4, 953, 10.1002/cam4.413
Ceccon, 2015, Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma, Mol Cancer Res, 13, 775, 10.1158/1541-7786.MCR-14-0157
Huang, 2016, Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase, J Med Chem, 59, 4948, 10.1021/acs.jmedchem.6b00306
Gettinger, Brigatinib (AP26113) efficacy and safety in ALK+ NSCLC: phase 1/2 trial results, J Thorac Oncol, 10, S238
Gehrke, 2011, Clinical pharmacology review. Xalkori, crizotinib
Brigatinib (data on file)
Ou, 2013, Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028), Eur J Cancer, 49, S19
Brower, 2014, Clinical pharmacology review. Zykadia, ceritinib
Zahalka, 2015, Clinical pharmacology review. Alecensa, alectinib